Trials / Completed
CompletedNCT03854903
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor (ASPIRE - WI231696)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Georgetown University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single-arm, phase I trial. It is designed with a conservative dose escalation plan to ensure patient's safety and with a strong translational component to inform if target inhibition is achieved. With concerns regarding safety, based on extensive available pharmacokinetic data and clinical efficacy experience, bosutinib will be given 5-days in a row followed by 2 days rest in a weekly basis, instead of daily. The protocol will enroll patients per 3+3 escalation design. The Dose Limiting Toxicity (DLT) observation period is 28 days. At the end of DLT observation period of each cohort of 3 patients, decision will be made regarding further escalation or de-escalation according to this plan. Once the MTD of the combination is reached, the safety data will be analyzed. There will be no dose reductions during DLT observation period. Dose reduction within patients (individually) is allowed after the 4-week DLT observation period. Treatment in this phase I trial will be administered until there is disease progression or unacceptable toxicity.
Conditions
- Metastatic Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Hormone Receptor Positive Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Palbociclib | Palbociclib is taken orally. |
| DRUG | Bosutinib | Bosutinib is taken orally. |
| DRUG | Fulvestrant | Fulvestrant is given as an intramuscular injection. |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2023-11-01
- Completion
- 2025-01-09
- First posted
- 2019-02-26
- Last updated
- 2025-02-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03854903. Inclusion in this directory is not an endorsement.